NIH licenses (patents, data) and comments on proposed exclusive licenses

See also: /government-funded-inventions


  • 2015: NIH refuses to give information about principals in company seeking exclusive license to HCV patents
  • 2015: Virotas Biopharmaceuticals. KEI and Public Citizen ask NIH for safeguards in license for HCV patents
  • 2016: AltraTech, KEI comments on NIH proposal for exclusive licenses for vitro diagnostics patents
  • 2016: Chimeron Bio: KEI comments on NIH proposal for exclusive license for patents on cancer treatments
  • 2016: Dedalus Pharma, LLC, KEI comments on NIH proposal for exclusive licenses on CARs to treat cancer
  • 2016: Great Lakes Neuroscience and NIH exclusive license on MS/ALS patent
  • 2016: KEI comments on NIH proposal for exclusive licenses to Dimension Therapeutics, Inc.
  • 2016: KEI comments on NIH proposal for exclusive licenses to Etubics Corporation
  • 2016: KEI comments on NIH proposal for exclusive licenses to IntelliPanel Medical, LLC
  • 2016: KEI comments on NIH proposal for exclusive licenses to Lentigen Technology, Inc.
  • 2016: KEI objections to NIH licenses to Vital Spark, Kalytera Therapeutics, CB1 receptor mediating compounds
  • 2016: KEI/MSF comments to NIH on licensing of patents on Attenuated Respiratory Syncytial Virus (RSV) Vaccines
  • 2016: Kite Pharma, KEI Comments on NIH Proposed Exclusive License for Cancer Treatment
  • 2016: MeiraGTx, NIH license of patents on AAV­Mediated Aquaporin Gene Transfer To Treat Sjögren’s Syndrome
  • 2016: Midissia Therapeutics license of NIH owned breast and prostate cancer vaccine patents
  • 2016: NIH FOIA office withholds all records related to exclusive license on HER2+ breast cancer treatment technology
  • 2016: NIH license on patents on 5T4 Antibodies for cancer treatment, diagnostics, to Ovensa, located in Ontario, Canada
  • 2016: NIH licenses on Boron Neutron patents, to Beijing Lanyears Communication
  • 2016: Objection to exclusive license to AestasRx Inc.
  • 2017: AbPro license of patents for liver cancer
  • 2017: Nanobernetics license
  • 2017: GeneXion Oncology Prospective Grant of Exclusive Patent License for Mutant IDH1 Inhibitors Useful for Treating Cancer
  • 2017: Nanobernetics proposed exclusive license for NIH patents on Apparatus for Microarray Binding Sensors
  • 2017: NantBioScience – Commercial Application and Use of Fulvestrant in Combination Therapy for the Treatment of Cancers
  • 2017: VeriLuce license of patents for pancreatic cancer treatment
  • 2017: miRecule/NIH license on MicroRNA Therapeutics for Treating Squamous Cell Carcinomas
  • KEI initial comments on NIH proposed grant of exclusive license on liver cancer treatment to Salubris
  • KEI statement regarding Gilead’s Acquisition of Kite Pharma
  • Kite Pharma Press Releases & News Stories Related to Relationship with National Cancer Institute
  • Kite Pharma Uses CRADAs to Conduct Important Clinical Research on New Cancer Treatments
  • NIH Waivers for U.S. Manufacturing Requirements for Federally-Funded Drugs
  • Paclitaxel, Taxol
  • Printer-friendly version Send by email Send by email